clinical trials

News

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.

News

Genmab has decided to stop development of a drug for cancer, acasunlimab for non-small cell lung cancer, following a review of its pipeline.

News

Two phase 3 trials of Ultragenyx and Mereo's sclerostin inhibitor setrusumab in osteogenesis imperfecta missed their primary efficacy objectives.

News

J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal.

News

AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.

R&D

We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.